0
Article ? AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button. Tier 2 ? Original research — experimental, observational, or case-control study. Direct primary evidence. Gut & Microbiome Human Health Effects Nanoplastics Sign in to save

Engineered Probiotics Mitigate Gut Barrier Dysfunction Induced by Nanoplastics

Advanced Science 2025 11 citations ? Citation count from OpenAlex, updated daily. May differ slightly from the publisher's own count.
Wenxin Chen, Qiyan Guo, Hong Li, Xue Chi, Xiang Ma, Yanqiong Tang, Quanfeng Liang, Zhu Liu, Yong Liu, Juanjuan Li

Summary

Researchers engineered a probiotic-based system using modified E. coli Nissle 1917 bacteria to counteract gut barrier damage caused by nanoplastics derived from PET food packaging. The engineered probiotic was designed to produce an anti-inflammatory protein and was coated for better survival in the digestive tract, where it reduced inflammation, restored gut barrier function, and rebalanced gut bacteria in animal models. The study suggests that engineered probiotics could be a promising approach for protecting the gut from nanoplastic-related damage.

Polymers
Study Type In vivo

Micro- and nanoplastics, particularly those derived from food-contact materials like polyethylene terephthalate (PET), can damage gut barriers, making the gastrointestinal system more vulnerable to inflammation and infections. Here, a probiotic-based drug delivery system (EcNT@L) is devised to mitigate nanoplastics-induced gut barrier dysfunction by modulating gut immunity and microbiota. Escherichia coli Nissle 1917 (EcN) is genetically engineered to produce transforming growth factor-β (TGF-β) and then modified with an Eudragit L100-55 coating. This engineered probiotic acts as an in vivo "drug factory", exerting anti-inflammatory and immune-regulatory effects, with improved retention and bioavailability in the gastrointestinal tract. EcNT@L effectively protects Caco-2 cells from inflammation and infections induced by nano PET, primarily by activating the NF-κB signaling pathway. Besides, EcNT@L demonstrates superior in vivo therapeutic efficacy in treating gastrointestinal infection caused by the combined presence of nano PET and Salmonella, outperforming commercial antibiotics due to its ability to modulate immune responses and gut microbiota. This study highlights the potential of probiotic-based drug delivery systems in addressing nanoplastics-induced gut dysfunctions, offering a promising strategy for mitigating the environmental impact of micro- and nanoplastics.

Share this paper